Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention generally relates a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof
• TLRs Toll-like receptors
• TLR7 and TLR8 have been shown to be expressed in endosomal compartments and to recognize ssRNA molecular patterns.
• TLR7 is expressed in B cells and plasmacytoid dendritic cells (pDC); TLR8 is expressed in monocytes and myeloid dendritic cells (mDC) (Chuang TH, Ulevitch RJ.. Eur Cytokine Net. 2000;11:372-378; Iwasaki A, Medzhitov R. Nat Immunol. 2004;5:987- 995).
• Cutaneous lupus erythematosus is a skin disorder which can occur as isolated skin manifestation or with concomitant systemic lupus erythematosus (SLE) (Okon LG, Werth VP. Best Pract Res Clin Rheumatol. 2013;27:391-404; Cohen MR, Crosby D. J Rheumatol. 1994;21:1665-1669).
• CLE is often associated with the presence of autoantibodies with varying frequency. Similar to SLE, Type I Interferon (IFN) dysregulation is proposed to be a key pathogenic driver in CLE.
• IFN Interferon
• CLE patients often present with IFN signature in blood and in skin lesions, with blood IFN signature correlating with skin disease activity score (Braunstein I, Klein R, Okawa J, et al., Br J Dermatol. 2012;166:971-975; Meller S, Winterberg F, GillietM, et al., Arthritis Rheum. 2005;52:1504-1516, Wenzel J, Zahn S, Mikus S, et al., Br J Dermatol. 2007;157:752-757).
• Plasmacytoid dendritic cells are specialized cells that accumulate in the skin of CLE patients and account for 5-10% of the immune infiltrate and have been proposed to be the major source of Type I IFN in CLE skin lesions.
• the pDCs robustly secrete IFNa in response to TLR7 and TLR9 stimulation by nucleic acid ligands, while TLR8 induces a variety of myeloid cells to produce proinflammatory cytokines such as TNFa and IL-6 (Siegal FP, Kadowaki N, Shodell M, et al. Science 1999;284:1835-1837; Tomasini D, Mentzel T, Hantschke M, et al., J Cutan Pathol. 2010;37:1132-1139; Vermi W, Lonardi S, Morassi M, et al., Immunobiology 2009;214:877-86).
• RNA ribonucleic acid
• DNA deoxyribonucleic acid
• New methods of treating CLE are desired.
• the present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.
• the present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof.
• the present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof.
• FIG. 1 shows the inhibition of cutaneous lesions following treatment with either Compound (I) or prednisolone in female MRL/lpr mice.
• FIG. 2 shows the reduction of erythema of cutaneous lesions treatment with either Compound (I) or prednisolone in female MRL/lpr mice.
• FIG 3 shows the inhibition of circulating antibody titers including anti-dsDNA, anti-smRNP and anti-Ro antibody titers following treatment with either Compound (I) or prednisolone.
• FIG 4 shows reduction in the proteinuria and urinary NGAL following treatment with either Compound (I) or prednisolone.
• FIG 5 shows Compound (I) inhibits TLR7-induced IL-6 in an ex vivo settings following treatment with either Compound (I) or prednisolone.
• FIG 6 shows the total lesions for the female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 7 shows the neck erythema score for female MRL/lpr mice treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 8 shows the ear erythema score for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 9 shows the total erythema score for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 10 shows the proteinuria levels for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 11 shows the urinary NGAL levels for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 12 shows the total lesions for the female MRL/lpr mice in advanced disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 13 shows the neck erythema score for female MRL/lpr mice treated with vehicle, Compound (I), prednisolone, and Compound (I) + prednisolone.
• FIG 14 shows the neck erythema score for female MRL/lpr mice treated with vehicle, hydroxychloroquine, and Compound (I) + hydroxychloroquine.
• FIG 15 shows the ear erythema score for female MRL/lpr mice in advanced disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• FIG 16 shows the total erythema score for female MRL/lpr mice in advanced disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.
• TR7 inhibitor inhibits the function of TLR7.
• TLR7 inhibitors can associate with TLR7 reversibly or irreversibly, and include antibodies, small molecules, and millimolecular compounds.
• the compound of Formula (I) is a TLR7 inhibitor and has the structure:
• the chemical name for the compound of Formula (I) is 2-(4-(2-(7,8-dimethyl- [l,2,4]triazolo[l,5-a]pyridin-6-yl)-3-isopropyl-lH-indol-5-yl)piperidin-l-yl)acetamide.
• the discovery and synthesis of the compound of Formula (I) is described in WO 2018/005586 Al.
• Prednisolone is a corticosteroid drug having the chemical name: 11,17-dihydroxy - 17-(2-hy droxy acetyl)- 10,13 -dimethyl-6,7, 8,9, 10,11,12,13,14,15,16,17- dodecahydrocyclopenta[a] phenanthren-3-one.
• Prednisolone can be orally administered as a tablet, an orally disintegrating tablet, a solution, or a suspension.
• Ophthalmic prednisolone is available as a solution (liquid) and a suspension (eye drops).
• Prednisolone is available as a sodium salt. Prednisolone can also be administered as the prodrug prednisone. As used herein “prednisolone” includes both prednisolone and prednisone. As used herein “Pred” refers to prednisolone.
• Hydroxychloroquine has the structure
• HCQ refers to hydroxychloroquine.
• Hydroxychloroquine is used to treat or prevent auto-immune diseases including lupus and rheumatoid arthritis. It can reduce skin problems in lupus, including cutaneous lupus erythematosus and prevent swelling/pain in arthritis.
• Hydroxychloroquine is available as a sulfate salt in which 200 mg of the sulfate salt is equal to 155 mg of the base.
• treat refers to any type of intervention or process performed on, or administering an active agent to, the patient with the objective of reversing, alleviating, ameliorating, inhibiting, or slowing down or preventing the progression, development, severity or recurrence of a symptom, complication, condition or biochemical indicia associated with a disease.
• Treatment includes therapeutic treatment and prophylactic or preventative measures, wherein the object is prevent or lessen the targeted condition or disorder.
• terapéuticaally effective amount or “therapeutically effective dosage” of a drug or therapeutic agent refers to an amount of a drug effective to treat a disease or disorder in a patient.
• an effective amount refers to an amount effective, at dosages and for period of time necessary, achieve the desired therapeutic or prophylactic result.
• the ability of a therapeutic agent to promote disease regression or inhibit the development or recurrence of the disease can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
• Therapeutically effective amounts of a TLR7 inhibitor, prednisolone, and hydroxychloroquine may vary according to factors such as the disease state, age, sex, and weight of the patient, and abilities of the TLR7 inhibitor, prednisolone, and hydroxychloroquine to elicit a desired response in the patient.
• Therapeutically effective amounts of the TLR7 inhibitor, prednisolone, and hydroxychloroquine encompasses an amount in which any toxic or detrimental effects of the TLR7 inhibitor, prednisolone, and hydroxychloroquine are outweighed by the therapeutically beneficial effects.
• administering refers to the physical introduction of a composition comprising a therapeutic agent to a patient, using any of the various methods and delivery systems known to those skilled in the art.
• Routes of administration for the TLR7 inhibitor and the second agent include enteral, topical, and mucosal administration such as oral, topical, sublingual, rectal, intranasal, and intravenous administration, and parenteral administration such as intravenous, intramuscular, and subcutaneous injection.
• Administration "in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive (sequential) administration in any order.
• the patient may swallow the oral dosage form of the TLR7 inhibitor and the oral dosage form for the second agent in either order (consecutive); or may swallow both oral dosage forms together (concurrent).
• patient includes human and other mammalian subjects that receive therapeutic treatment.
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof; and a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisone or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor.
• a method in which the TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor.
• a method in which the TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor.
• a method in which the TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor.
• a method in which the TLR7 inhibitor is administered prior to the administration of the second agent.
• the TLR7 agent is administered after the second agent.
• TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor.
• a method in which the TLR7 inhibitor is administered prior to the administration of the second agent.
• the TLR7 agent is administered after the second agent.
• TLR7 inhibitor is the compound of Formula (I).
• One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor.
• a method in which the TLR7 inhibitor is administered prior to the administration of the second agent.
• the TLR7 agent is administered after the second agent.
• TLR7 inhibitor is the compound of Formula (I).
• a therapeutically effective dose of the compound of Formula (I) is in the range of 0.1 to 100 mg.
• a therapeutically effective dose of the compound of prednisolone is in the range of 0.5 to 50 mg.
• a therapeutically effective dose of the compound of hydroxychloroquine is in the range of 1 to 20 mg.
• the therapeutically effective dose of the TL7 inhibitor can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.
• the therapeutically effective dose of prednisolone can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.
• the therapeutically effective dose of hydroxychloroquine can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.
• the therapeutically effective dose of the TLR7 inhibitor is administered as a single daily dose.
• the therapeutically effective dose of the compound of Formula (I) is administered as a single daily dose.
• the therapeutically effective dose of prednisolone is administered as a single daily dose.
• the therapeutically effective dose of hydroxychloroquine is administered as a single daily dose.
• the therapeutically effective dose of the TLR7 inhibitor is administered as a single daily dose and the therapeutically effective dose of the second agent selected from prednisolone and hydroxychloroquine is administered as a single dose.
• the TLR7 inhibitor and the second agent are administered once a day, wherein the TLR7 inhibitor and the second agent are administered simultaneously, or the TLR7 inhibitor is administered immediately before or after the administration of the second agent.
• the TLR7 inhibitor is the compound of Formula (I).
• the second agent is prednisolone.
• included in this embodiment is a method in which the second agent is hydroxychloroquine.
• a therapeutically effective dose of prednisolone is administered as a single daily dose.
• a therapeutically effective dose of hydroxychloroquine is administered as a single daily dose.
• the therapeutically effective dose of the TLR7 inhibitor is administered as a twice daily dose and the therapeutically effective dose of the second agent is administered either one or twice daily dose. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
• the therapeutically effective dose of the TLR7 inhibitor is administered as a twice daily dose and the therapeutically effective dose of the second agent selected from prednisolone and hydroxychloroquine is administered as a twice dose.
• the TLR7 inhibitor is the compound of Formula (I).
• the second agent is prednisolone.
• included in this embodiment is a method in which the second agent is hydroxychloroquine.
• the method of treating a patient having cutaneous lupus erythematosus comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, and in combination with one or more addition third agents.
• suitable third agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin- 10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as dexamethasone; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-a inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof.
• CSAIDs cytokine-suppressive anti
• the above third agents when employed in combination with the combinations of Compound (I) and the second agent, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
• the one or more third agents may be administered prior to, simultaneously with, or following the administration of Compound (I) or the second agent.
• mice were group housed in Syngene Laboratory Animal Research Facility (SLAR, Bangalore India; AAALAC accredited), and maintained under normal 12 h light /12 h dark cycle with ad libitum access to food and water. At the end of the studies, animals were euthanized by CO2 asphyxiation for plasma and tissue collection.
• mice of 12 to 14 weeks of age were screened and randomized based on the titers of anti-dsDNA antibodies and urinary neutrophil gelatinase-associated lipocalin (NGAL).
• Mice were treated orally, once daily for 8 weeks with vehicle (10% ethanol; 45% PEG 300; 5% Pluronic F-68; 40% 20 mM citrate buffer) or different doses of test compound (Compound (I)) or reference (prednisolone) compound.
• vehicle 10% ethanol; 45% PEG 300; 5% Pluronic F-68; 40% 20 mM citrate buffer
• test compound Compound (I)
• reference prednisolone
• the severity of skin lesions was assessed every week by counting the number of lesions as well as erythema (on the scale of 0 to 4, considering zero - none; 1 - mild, 2 - moderate, 3 -moderate to severe and 4 - very marked and severe).
• Total erythema was derived by adding the erythema scores of neck, head, ear and face lesions. Since female MRL/lpr mice also develop nephritis in addition to cutaneous lesions, the effect of vehicle, test or reference compounds on renal disease were evaluated by measuring proteinuria, urinary NGAL and autoantibody titers like anti-Ro, anti-smRNP and anti-dsDNA Ab titer.
• mice were bled at various time points to capture the complete pharmacokinetic profile of the test or reference compound and also the extent of inhibition of gardiquimod-induced IL-6 in an ex vivo whole blood assay.
• Spleen samples were taken at the end of the study to measure the impact of treatment on IL-6 and IFNa- producing cell population by flow cytometry.
• Blood samples were analyzed for gene expression by qPCR and for TLR7 target coverage utilizing an ex vivo blood assay of gardiquimod induced IL-6 production.
• Statistical analysis was done using one-way ANOVA with Dunnett’s test to calculate the significance of test or reference compound treated groups vs. vehicle control group. Percent reduction in disease severity was calculated for each parameter, for test or reference compound treated groups vs. vehicle control group.
• mice develop cutaneous lesions in a spontaneous manner, making this a widely accepted preclinical murine model of cutaneous lupus. In addition to cutaneous manifestations, these mice also showed kidney injury. Compound was investigated for its effects on both skin lesions and on kidney injury markers in this model. In this study, mice were randomized based on urinary NGAL and anti-dsDNA Ab titer. Immediately after recruitment, mice were treated with Compound (I) and prednisolone for 8 weeks.
• Figure 1 Inhibition of cutaneous lesions in female MRL/lpr mice following treatment with Compound (I). Mice were dosed orally for 8 weeks. . Skin lesions were then assessed on neck (A), head (B), face (C), and ear (D). The impact of treatment on the total lesions were also represented by adding the number of lesions present on face, neck, head, and ear.
• E Data are from one experiment with 13 to 15 mice per group. *P ⁇ 0.01, **P ⁇ 0.001, ***p ⁇ 0.0001 versus vehicle by two-way ANOVA with a Bonferroni test.
• FIG. 2 Treatment of female MRL/lpr mice with Compound (I) suppressed erythema of cutaneous lesions. Mice were dosed orally for 8 weeks. Erythema of skin lesions were assessed on neck (A) and ear (B). The impact of treatment on the total erythema was also represented by assessing the erythematous score of skin lesions present on back, face, neck, ear and head (C). Data are from one experiment with 13 to 15 mice per group. *P ⁇ 0.01, **P ⁇ 0.001, ***P ⁇ 0.0001 versus vehicle by two-way ANOVA with a Bonferroni test.
• FIG. 3 Inhibition of autoantibodies in female MRL/lpr mice treated with Compound (I). Mice were dosed orally for 8 weeks with respective treatment. Following 8 weeks of dosing, anti-dsDNA (A) and anti-Ro (B) and anti-smRNP antibody titers (C) were assessed. Data are from one experiment with 13 to 15 mice per group. Percent inhibition relative to the vehicle group is shown above each bar. *P ⁇ 0.01, **P ⁇ 0.001, ***P ⁇ 0.0001 versus vehicle by one-way ANOVA with a Dunnett’s test.
• FIG. 4 Inhibition of kidney injury markers in female MRL/lpr mice treated with Compound (I). Mice were dosed orally for 8 weeks with respective treatment. Following 8 weeks of dosing, proteinuria (A) and urinary NGAL (B) were assessed. Data are from one experiment with 13 to 15 mice per group. Percent inhibition relative to the vehicle group is shown above each bar. *P ⁇ 0.01, **P ⁇ 0.001, ***P ⁇ 0.0001 versus vehicle by one-way ANOVA with a Dunnett’s test.
• Figure 5 Compound (I) inhibited TLR7-dependent IL-6 induction in an ex vivo assay in female MRL/lpr model of lupus. Mice were dosed orally for 7 weeks with respective treatment. Following 7 weeks of dosing, mouse whole blood was drawn at different time points and challenged with gardiquimod for 16 to 18 hours. IL-6 inhibition was assessed by ELISA. Data are from one experiment in which measurements were made in three mice per group per time point. Treatment with Compound (I) improved survival of mice in Female MRL/lpr model of lupus compared to vehicle
• NA Abbreviation: NA, not applicable.
• Compound (I) showed significant and robust dose- dependent suppression of cutaneous manifestations as assessed by measuring the number of lesions on face, neck, head, and ear.
• the impact of treatment on the total lesions were also represented by adding the number of lesions present on face, neck, head, and ear.
• the effect of Compound (I) was also evaluated by assessing the erythema on neck and ear and represented individually.
• skin lesions were also evaluated for total erythema after assessing the erythema of skin lesions present on back, face, neck, ear and head.
• a significant reduction in the erythema upon treatment with Compound (I) was observed Figure 2.
• Representative images of lesions in mice treated with Compound (I) and vehicle mice at the 8 week time point are shown in Figure 3.
• Total skin lesions score includes cumulative score of Neck/Back, Face, Head and Ear lesions
• Figure 6 Treatment with Compound (I) suppressed the total number of cutaneous lesions in mice in established disease compared to treatment with vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of cutaneous lesions but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.
• Figure 7 Treatment with Compound (I) suppressed erythema of cutaneous lesions on the neck of mice in established disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the neck of mice. Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the neck of mice.
• Figure 8 Treatment with Compound (I) suppressed erythema of cutaneous lesions on the ear of mice in established disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the ear of mice but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression of erythema of cutaneous lesions compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.
• Figure 9 Treatment with Compound (I) suppressed total erythema of cutaneous lesions on mice in established disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice. Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice.
• Figure 10 Treatment with Compound (I) showed suppression of the kidney injury marker proteinuria and urinary neutrophill gelatinase-associated lipocalin (NGAL) in established disease. Monotherapy with prednisolone or hydroxychloroquine showed suppression of the kidney injury marker proteinuria. The combination of Compound (I) with Prednisolone and the combination of Compound (I) with hydroxychloroquine showed increased suppression of the kidney injury marker proteinuria.
• NGAL urinary neutrophill gelatinase-associated lip
• FIG 11 Treatment with Compound (I) showed suppression of the kidney injury marker urinary NGAL in established disease.
• Monotherapy with prednisolone or hydroxychloroquine showed suppression of the kidney injury marker urinary NGAL.
• the combination of Compound (I) with Prednisolone and the combination of Compound (I) with hydroxychloroquine showed increased suppression of the kidney injury marker urinary NGAL.
• mice of 16 weeks of age were treated for 5 weeks. Mice were recruited when they showed group average of total skin lesions score as 2 to 2.5. Total skin lesions score includes cumulative score of Neck/Back, Face, Head and Ear lesions. Table 2 shows the treatments, doses, and number of mice in each treatment group. TABLE 4
• Figure 12 Treatment with Compound (I) suppressed the total number of cutaneous lesions in mice in advanced disease compared to treatment with vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of cutaneous lesions but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.
• Figure 13 Treatment with Compound (I) suppressed erythema of cutaneous lesions on the neck of mice in advanced disease compared to vehicle. Monotherapy with prednisolone showed suppression of erythema of cutaneous lesions on the neck of mice. Treatment with the combination of Compound (I) + prednisolone showed suppression of erythema of cutaneous lesions on the neck of mice.
• Figure 14 Treatment with Compound (I) suppressed erythema of cutaneous lesions on the neck of mice in advanced disease compared to vehicle. Monotherapy with hydroxychloroquine showed suppression of erythema of cutaneous lesions on the neck of mice. Treatment with the Compound (I) and treatment with the combination of Compound (I) + hydroxychloroquine showed increased suppression of erythema of cutaneous lesions on the neck of mice compared the treatment with hydroxychloroquine.
• Figure 15 Treatment with Compound (I) suppressed erythema of cutaneous lesions on the ear of mice in advanced disease compared to vehicle.
• Monotherapy with prednisolone and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the ear of mice but less than treatment with Compound (I).
• Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression of erythema of cutaneous lesions compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.
• Figure 16 Treatment with Compound (I) suppressed total erythema of cutaneous lesions on mice in advanced disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice. Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Transplantation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=76959055

Family Applications (1)

Country Status (11)

Cited By (4)

Citations (1)

Family Cites Families (4)

• 2021
  • 2021-06-10 KR KR1020237000739A patent/KR20230023717A/ko active Pending
  • 2021-06-10 CN CN202180040836.2A patent/CN115701995A/zh active Pending
  • 2021-06-10 WO PCT/US2021/036740 patent/WO2021252718A1/en not_active Ceased
  • 2021-06-10 MX MX2022015760A patent/MX2022015760A/es unknown
  • 2021-06-10 EP EP21742945.5A patent/EP4164639A1/en active Pending
  • 2021-06-10 JP JP2022575941A patent/JP7751597B2/ja active Active
  • 2021-06-10 US US18/009,035 patent/US20230310408A1/en active Pending
  • 2021-06-10 AU AU2021286582A patent/AU2021286582A1/en active Pending
  • 2021-06-10 CA CA3181964A patent/CA3181964A1/en active Pending
  • 2021-06-10 BR BR112022024999A patent/BR112022024999A2/pt unknown
  • 2021-06-10 IL IL298667A patent/IL298667A/en unknown
• 2025
  • 2025-09-26 JP JP2025159926A patent/JP2025183420A/ja active Pending

Patent Citations (1)

Non-Patent Citations (17)

Also Published As

Similar Documents

Legal Events